clinical trial · NCT07201051
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
BronchiectasisGSK3862995BPlacebo
brief summary
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.
started
Oct 30, 2025
primary completion
May 4, 2027
completion
Dec 10, 2027
last updated
Jul 2, 2026
official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Investigate Efficacy, Safety, Immunogenicity, and Pharmacokinetics, of GSK3862995B in Participants With Bronchiectasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol